First North's big fish

As the newest biotech on NASDAQ First North in Stockholm, InDex Pharmaceuticals Holding AB (SSE:INDEX) expects it will receive more attention from investors, as well as have less onerous and costly reporting requirements, compared with listing on the main board NASDAQ Stockholm exchange.

The ulcerative colitis company raised SEK250 million ($28.7 million) through the sale of 29.8 million shares at SEK8.40 on Sept. 30 and began trading on Oct. 11. ...